Biological ageing and healthspan endpoints — indication assessment
Interventions proposed to modify rate of biological ageing, assessed by composite biomarker clocks, functional measures, or mortality.
§1Assessment
§1.1Definition
Interventions proposed to modify rate of biological ageing, assessed by composite biomarker clocks, functional measures, or mortality.
§1.2Anchor and additional outcomes
The Institute designates one anchor outcome per indication so that estimates for different compounds are reported on a common measure. The anchor for this indication is the first outcome below.
- Epigenetic age acceleration
- Frailty index
- Functional capacity
- All-cause mortality
§1.3State of the evidence
The Institute assesses 9 compounds in this indication, drawing on 4 trial records and 1 evidence synthesis. No compound is graded above low certainty in this indication, which the Institute records as the principal finding for it.[1,2]
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Khavinson VK, Kuznik BI, Tarnovskaya SI, Linkova NS. Peptides and CCL11 and HMGB1 as differently expressed age-dependent proinflammatory biomarkers of ageing. Advances in Gerontology 2020;10(1):1–8. identifier not held by the Institute The digital object identifier previously carried on this record did not resolve and has been withdrawn. Journal and year are retained.
- D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.